Russia's RDIF signs deal to produce Sputnik V vaccine in China
RDIF, which is marketing Sputnik V globally, said that commercial production was due to start in May
A nurse prepares Russia's "Sputnik-V" vaccine for inoculation in a post-registration trials stage at a clinic in Moscow. Photo: Reuters
Russia's RDIF sovereign wealth fund and China's Shenzhen Yuanxing Gene-tech have agreed to produce over 60 million doses of Russia's Sputnik V vaccine against Covid-19 in China, RDIF said on Monday.
RDIF, which is marketing Sputnik V globally, said that commercial production was due to start in May.
Keep updated, follow The Business Standard's Google news channel
